| | | Page | | |||
| | | | | | ||
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 10 | | | |
| | | | | | ||
| | | | | | ||
| | | | 13 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | 22 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | 30 | | | |
| | | | | | ||
| | | | | | ||
| | | | ||||
| |
| | | Page | | |||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | ||||
| |
Name | | Class | | Age | | Position(s) | | Director Since | | Current Term Expires | | Expiration of Term For Which Nominated | | | Class | | Age | | Position(s) | | Director Since | | Current Term Expires | | Expiration of Term For Which Nominated | | ||||||||||||
1. Directors Whose Terms Expire at the Annual Meeting and Who Are Nominees for Terms Expiring at the 2025 Annual Meeting | | | | | | | | | | | | | | |||||||||||||||||||||||||
1. Directors Whose Terms Expire at the Annual Meeting and Who Are Nominees for Terms Expiring at the 2026 Annual Meeting | | | | | | | | | | | | | | |||||||||||||||||||||||||
Steven Ratoff(1)(2) | | III | | 80 | | Director | | 2007 | | 2023 | | 2026 | | |||||||||||||||||||||||||
Robert Glenning(1)(2)(3) | | III | | 62 | | Director | | 2016 | | 2023 | | 2026 | | |||||||||||||||||||||||||
2. Continuing Directors Whose Terms Do Not Expire at the Annual Meeting | | | | | | | | | | | | | | |||||||||||||||||||||||||
Michael Graves(1)(3) | | I | | 60 | | Chairman of the Board | | 2013 | | 2024 | | — | | |||||||||||||||||||||||||
Richard A. Edlin(2)(3) | | I | | 62 | | Director | | 2017 | | 2024 | | — | | |||||||||||||||||||||||||
Scott Tarriff(4) | | II | | 63 | | CEO/Director | | 2007 | | 2022 | | 2025 | | | II | | 63 | | CEO/Director | | 2007 | | 2025 | | — | | ||||||||||||
Jennifer K. Simpson(3)(4) | | II | | 53 | | Director | | 2019 | | 2022 | | 2025 | | |||||||||||||||||||||||||
Luciana Borio(4) | | II | | 51 | | Director | | 2021 | | 2022 | | 2025 | | |||||||||||||||||||||||||
2. Continuing Directors Whose Terms Do Not Expire at the Annual Meeting | | | | | | | | | | | | | | |||||||||||||||||||||||||
Steven Ratoff(1)(2) | | III | | 79 | | Director | | 2007 | | 2023 | | — | | |||||||||||||||||||||||||
Robert Glenning(1)(3) | | III | | 62 | | Director | | 2016 | | 2023 | | — | | |||||||||||||||||||||||||
Michael Graves(1)(2)(3) | | I | | 59 | | Chairman of the Board | | 2013 | | 2024 | | — | | |||||||||||||||||||||||||
Richard A. Edlin(2)(3) | | I | | 61 | | Director | | 2017 | | 2024 | | — | | |||||||||||||||||||||||||
Jennifer K. Simpson(2)(3)(4) | | II | | 54 | | Director | | 2019 | | 2025 | | — | | |||||||||||||||||||||||||
Luciana Borio(3)(4) | | II | | 52 | | Director | | 2021 | | 2025 | | — | |
| | Board Diversity Matrix (As of June 15, 2022) | | | ||||||||||||||||
| | Total Number of Directors | | | | 7 | | | ||||||||||||
| | | | | | Female | | | | Male | | | | Non- Binary | | | | Did Not Disclose Gender | | |
| | Part I: Gender Identity | | | ||||||||||||||||
| | Directors | | | | 2 | | | | 4 | | | | — | | | | 1 | | |
| | Part II: Demographic Background | | | ||||||||||||||||
| | African American or Black | | | | — | | | | — | | | | — | | | | — | | |
| | Alaskan Native or Native American | | | | — | | | | — | | | | — | | | | — | | |
| �� | Asian | | | | — | | | | — | | | | — | | | | — | | |
| | Hispanic or Latinx | | | | — | | | | — | | | | — | | | | — | | |
| | Native Hawaiian or Pacific Islander | | | | — | | | | — | | | | — | | | | — | | |
| | White | | | | 1 | | | | 4 | | | | — | | | | — | | |
| | Two or More Races or Ethnicities | | | | 1 | | | | — | | | | — | | | | — | | |
| | LGBTQ+ | | | | — | | | ||||||||||||
| | Did Not Disclose Demographic Background | | | | 1 | | |
| | Board Diversity Matrix (As of May 1, 2023) | | | ||||||||||||||||
| | Total Number of Directors | | | | 7 | | | ||||||||||||
| | | | | | Female | | | | Male | | | | Non- Binary | | | | Did Not Disclose Gender | | |
| | Part I: Gender Identity | | | ||||||||||||||||
| | Directors | | | | 2 | | | | 4 | | | | — | | | | 1 | | |
| | Part II: Demographic Background | | | ||||||||||||||||
| | African American or Black | | | | — | | | | — | | | | — | | | | — | | |
| | Alaskan Native or Native American | | | | — | | | | — | | | | — | | | | — | | |
| | Asian | | | | — | | | | — | | | | — | | | | — | | |
| | Hispanic or Latinx | | | | — | | | | — | | | | — | | | | — | | |
| | Native Hawaiian or Pacific Islander | | | | — | | | | — | | | | — | | | | — | | |
| | White | | | | 1 | | | | 4 | | | | — | | | | — | | |
| | Two or More Races or Ethnicities | | | | 1 | | | | — | | | | — | | | | — | | |
| | LGBTQ+ | | | | — | | | ||||||||||||
| | Did Not Disclose Demographic Background | | | | 1 | | |
| | Fiscal Year Ended December 31, | | | Fiscal Year Ended December 31, | | ||||||||||||||||||||
| | 2021 | | 2020(1) | | | 2022 | | 2021 | | ||||||||||||||||
Audit Fees | | | $ | 829,000 | | | | $ | 625,000 | | | | | $ | 1,689,000 | | | | $ | 829,000 | | | ||||
Total Fees | | | $ | 829,000 | | | | $ | 625,000 | | | | | $ | 1,689,000 | | | | $ | 829,000 | | |
Name | | | Age | | | Position(s) | |
Executive Officers | | | | | | | |
Scott Tarriff | | | | | Chief Executive Officer, President, Director | | |
Brian Cahill | |||||||
| | 54 | | | Chief | |
| | Beneficial Ownership | | | Beneficial Ownership | | ||||||||||||||||||||
Name and Address of Beneficial Owner(1) | | Number of Shares (#) | | Percentage of Total (%) | | | Number of Shares (#) | | Percentage of Total (%) | | ||||||||||||||||
More than 5% stockholders: | | | | | | | | | | | | | | | | | | | | | | | ||||
BlackRock, Inc.(2) | | | | 1,968,816 | | | | | 15.5 | | | | | | 1,872,901 | | | | | 14.3 | | | ||||
Janus Capital Management LLC(3) | | | | 1,528,152 | | | | | 12.0 | | | | | | 1,229,872 | | | | | 9.4 | | | ||||
The Vanguard Group, Inc.(4) | | | | 760,468 | | | | | 6.0 | | | | | | 763,807 | | | | | 5.8 | | | ||||
State Street Corporation(5) | | | | 708,224 | | | | | 5.6 | | | | | | 952,026 | | | | | 7.3 | | | ||||
Named Executive Officers and Directors: | | | | | | | | | | | | | | | | | | | | | | | ||||
Scott Tarriff(6) | | | | 2,452,478 | | | | | 18.0 | | | | | | 2,630,864 | | | | | 18.7 | | | ||||
Brian Cahill(7) | | | | 55,822 | | | | | * | | | | | | 101,295 | | | | | * | | | ||||
Michael Moran(8) | | | | 67,249 | | | | | * | | | | | | — | | | | | — | | | ||||
Steven Ratoff(9) | | | | 115,544 | | | | | * | | | | | | 126,744 | | | | | 1.0 | | | ||||
Jennifer K. Simpson(10) | | | | 33,222 | | | | | * | | | | | | 44,700 | | | | | * | | | ||||
Michael Graves(11) | | | | 1,106,163 | | | | | 8.6 | | | | | | 1,117,363 | | | | | 8.5 | | | ||||
Luciana Borio(12) | | | | 5,625 | | | | | * | | | | | | 20,575 | | | | | * | | | ||||
Robert Glenning(13) | | | | 63,500 | | | | | * | | | | | | 74,700 | | | | | * | | | ||||
Richard A. Edlin(14) | | | | 85,240 | | | | | * | | | | | | 87,300 | | | | | * | | | ||||
Judith Ng-Cashin(15) | | | | 9,479 | | | | | * | | | |||||||||||||||
David Pernock(16) | | | | 248,426 | | | | | 1.9 | | | |||||||||||||||
All current directors and executive officers as a group (9 persons)(17) | | | | 3,984,843 | | | | | 28.2 | | | |||||||||||||||
All current directors and executive officers as a group (8 persons)(15) | | | | 4,203,541 | | | | | 28.9 | | |
Name | | | Position(s) | |
Scott Tarriff | | | Chief Executive Officer and President | |
Brian Cahill | | | Chief Financial | |
Michael Moran(1) | | | Former Chief Commercial Officer | |
|
Element of Compensation | | | Objectives | | | Key Features | |
Base Salary (fixed cash) | | | Provides financial stability and security through a fixed amount of cash for performing job responsibilities. | | | Generally reviewed annually at the beginning of the year and determined based on a number of factors (including individual performance, internal parity, retention, expected cost of living increases and the overall performance of our Company) and by reference to market data provided by our compensation committee’s compensation consultant. | |
Performance Bonus (at-risk cash) | | | Motivates and rewards for attaining rigorous annual corporate performance goals that relate to our key business objectives. | | | Target annual performance bonus opportunities, which are expressed as a percentage of base salary, are generally reviewed annually and determined based upon positions that have similar impact on the organization and competitive bonus opportunities in our market. Actual bonus payments are dependent upon the achievement of specific corporate performance objectives, generally determined by our compensation committee and our Board. | |
| | | | | | Actual bonus amounts earned are determined after the end of the year, based on achievement of the designated corporate performance objectives and individual executives’ performance and contributions to these corporate achievements. |
| |||||||
Long-Term Incentive | | | Motivates and rewards for long-term company performance; aligns executives’ interests with stockholder interests and changes in stockholder value. Attracts highly qualified executives and encourages their continued employment over the long-term. | | | Annual equity awards are generally reviewed and determined at the beginning of each year or as appropriate during the year for new hires, promotions, or reward for significant achievement. Individual awards are determined based on a number of factors, including current corporate and individual performance, outstanding equity holdings and their retention value and total ownership, historical value of our stock, internal parity among executives and competitive market data provided by our compensation committee’s compensation consultant. | |
Element of Compensation | | | Objectives | | | Key Features | |
| | | | | | Equity awards have been historically provided in the form of stock | |
| Agenus (AGEN) Amphastar Pharmaceuticals (AMPH) Catalyst Pharmaceuticals (CPRX)* Clovis Oncology (CLVSQ) Coherus BioSciences (CHRS) Collegium Pharmaceutical (COLL) | | | Corcept Therapeutics (CORT) Global Blood Therapeutics (GBT)* Intercept Pharmaceuticals (ICPT)* Lannett Co. (LCI) Ligand Pharmaceuticals (LGND) Nektar Therapeutics (NKTR) | | | ||
Pacira BioSciences (PCRX) Puma Biotechnology | ||||||||
(PBYI) Supernus Pharmaceuticals | ||||||||
Vanda Pharmaceuticals | ||||||||
|
Named Executive Officer | | 2021 Base Salary | | Increase from 2020 Base Salary | | | 2022 Base Salary | | Increase from 2021 Base Salary | | ||||||||||||||||
Scott Tarriff | | | $ | 816,000 | | | | | 3% | | | | | $ | 848,640 | | | | | 4% | | | ||||
Brian Cahill | | | $ | 380,000 | | | | | — | | | | | $ | 395,200 | | | | | 4% | | | ||||
Michael Moran | | | $ | 397,000 | | | | | 3% | | | | | $ | 474,032 | | | | | 4% | | | ||||
David Pernock | | | $ | 602,000 | | | | | 3% | | | |||||||||||||||
Judith Ng-Cashin, M.D. | | | $ | 412,000 | | | | | 0.5% | | |
| | Goals | | | | Achievements | | | | Bonus Funding | | |
| | Product Sales (10%) 1. Obtaining or exceeding the Ryanodex product sales goal for 2. Obtaining or exceeding the Belrapzo product sales goal for 3. Obtaining or exceeding the Vasopressin product sales goal for 2022 of $87.4 million | | | | Partially achieved goals based on the following: 1. Achieved 2. Achieved 3. Achieved 72% ($63.2 million) of Vasopressin sales goal 4. Achieved 43% ($67.5 million) of PEMFEXY sales goal | | | | | |
| | 4. Obtaining or exceeding the PEMFEXY® product sales goal for 2022 of $156.1 million | | | | | | | | | | |
| | Earnings (10%) 1. Adjusted Non-GAAP EPS(1) Target 2. Adjusted Non-GAAP EBITDA(1) Target | | | | Achieved goals based on the following: 1. Adjusted Non-GAAP EPS(1) for the twelve months ended December 31, 2. Adjusted Non-GAAP EBITDA(1) for the twelve months ended December 31, | | | | 8% | | |
| | Vasopressin (10%)(2) 1. Achieve positive outcome in litigation concerning Par’s patent infringement claims against Eagle 2. Launch vasopressin and generate revenues | | | | Achieved goals based on the following: 1. Obtained U.S. Court of Appeals for Federal Circuit holding that vasopressin does not infringe any of the patents Par asserted 2. The Company launched vasopressin in January 2022 and achieved the Company’s peak market share in July and August 2022 of 27% | | | | 10% | | |
| | 1. | | | | Goal not achieved | | | | 0% | | |
| | Pemfexy (10%) 1. Initiate commercial launch | | | | Achieved goals based on the following: 1. The Company | | | | | | |
| | 1. 2. Patents and clinical study planning | | | | Achieved goals based on the following: 1. 2. The Company filed a new | | | | |||
| | |||||||||||
| | Bendamustine 1. Achieve positive outcomes in various bendamustine patent litigation matters 2. Maintain continuous rapidly infused bendamustine (“Bendeka”) and bendamustine ready-to-dilute 500ml solution (“Belrazpo”) commercial supply | | | | Achieved goals based on the following: 1. 2. Maintained continuous supply of Bendeka and Belrapzo throughout | | | | 4% | | |
| | Corporate Governance (10%) 1. Investor outreach—establish and maintain comprehensive engagement with investors 2. Organizational development initiatives | | | | Achieved goals based on the following: 1. Management engaged shareholders through shareholder outreach regarding corporate governance and compensation practices 2. Organizational changes maximized sales efforts and clinical development capabilities to promote current and future success | | | | 10% | | |
| | Barhemsys and ByFavo (10%) 1. Build sales team to maximize sales opportunity | | | | Achieved goals based on the following: 1. Scaled up hospital sales team with highly qualified key account managers 2. Successfully integrated Acacia operations in 2022 | | | | 10% | | |
| | 1. 2. New patent filing | | | | Achieved goals based on the following: 1. 2. Developed lifecycle management plan | | | | | | |
| | Additional 1. M&A/ Business Development Licensing 2. Obtain financing for corporate development as necessary 3. Obtain additional Bendamustine patents/settlements | | | | Partially achieved goals based on the following: 1. Achieved M&A/Business Development Licensing stretch goal based on the following: a. Entered into b. Acquired Acacia Pharma in June 2022, which added two FDA approved new chemical entities with patent protection 2. Amended credit facility with JP Morgan and other new banks 3. Settled outstanding suits with Hospira and Accord | | | | | | |
| | |||||||||||
TOTAL | | | | | | | | | |
Named Executive Officer | | 2021 Target Bonus (% of Base Salary) | | 2021 Target Bonus ($) | | 2021 Actual Bonus ($) | | Actual Bonus as a % of Target Bonus | | | 2022 Target Bonus (% of Base Salary) | | 2022 Target Bonus ($) | | 2022 Actual Bonus ($) | | Actual Bonus as a % of Target Bonus | | ||||||||||||||||||||||||||||||||
Scott Tarriff | | | | 100% | | | | $ | 816,000 | | | | $ | 1,338,240 | | | | | 164% | | | | | | 100% | | | | $ | 848,640 | | | | $ | 636,705 | | | | | 75% | | | ||||||||
Brian Cahill | | | | 60% | | | | $ | 228,000 | | | | $ | 373,920 | | | | | 164% | | | | | | 60% | | | | $ | 237,120 | | | | $ | 177,840 | | | | | 75% | | | ||||||||
Michael Moran(1) | | | | 60% | | | | $ | 255,206 | | | | $ | 418,540 | | | | | 164% | | | | | | 60% | | | | $ | 284,419 | | | | $ | — | | | | | 75% | | | ||||||||
David Pernock(2) | | | | 60% | | | | $ | 361,200 | | | | $ | — | | | | | — | | | |||||||||||||||||||||||||||||
Judith Ng-Cashin, M.D.(2) | | | | 60% | | | | $ | 247,200 | | | | $ | — | | | | | — | | |
Named Executive Officer | | | PSUs | | RSUs | | ||||||||||||||||||||||||||||||||
| | | | | | PSUs | | RSUs | | |||||||||||||||||||||||||||||
Named Executive Officer | | | rTSR PSU Grant (Target # shares) | | Milestone PSU Grant (Target # shares) | | RSU Grant (# shares) | | | Total Target Grant Value | | PSU Grant (Target # shares) | | RSU Grant (# shares) | | |||||||||||||||||||||||
| | | 60,400 | | | | | 25,900 | | | | | — | | | | | $ | 7,038,000 | | | | | 104,500 | | | | | 34,800 | | | |||||||
Brian Cahill | | | | 8,900 | | | | | 7,600 | | | | | 8,900 | | | | | $ | 1,622,000 | | | | | 24,100 | | | | | 8,000 | | | ||||||
Michael Moran | | | | 8,200 | | | | | 7,100 | | | | | 8,200 | | | | | $ | 2,095,000 | | | | | 31,100 | | | | | 10,400 | | | ||||||
David Pernock | | | | 9,700 | | | | | 8,300 | | | | | 9,700 | | | ||||||||||||||||||||||
Judith Ng-Cashin, M.D. | | | | 2,000 | | | | | 1,700 | | | | | 2,000 | | |
Name and Principal Position | | Year | | Salary ($) | | Bonus ($) | | Stock Awards ($)(1) | | Option Awards ($)(1) | | Non-Equity Incentive Plan Compensation ($)(2) | | All Other Compensation ($)(3) | | Total ($) | | | Year | | Salary ($) | | Bonus ($) | | Stock Awards ($)(1) | | Option Awards ($)(1) | | Non-Equity Incentive Plan Compensation ($)(2) | | All Other Compensation ($)(3) | | Total ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Scott Tarriff President, Chief Executive Officer, Director | | | | | 2021 | | | | | 815,914 | | | | | — | | | | | 4,293,836 | | | | | — | | | | | 1,338,700 | | | | | 23,071 | | | | | 6,471,521 | | | | | | | 2022 | | | | | 848,940 | | | | | — | | | | | 9,011,197 | | | | | — | | | | | 636,705 | | | | | 23,735(4) | | | | | 10,520,577 | | | ||||||||||||||
| | | 2020 | | | | | 822,093 | | | | | — | | | | | 3,485,757 | | | | | 4,584,223 | | | | | 554,750 | | | | | 22,610 | | | | | 9,469,433 | | | | | | 2021 | | | | | 815,914 | | | | | — | | | | | 4,293,836 | | | | | — | | | | | 1,338,700 | | | | | 23,071 | | | | | 6,471,521 | | | |||||||||||||||||
| | | 2019 | | | | | 769,410 | | | | | — | | | | | 2,599,120 | | | | | 2,955,330 | | | | | 1,538,800 | | | | | 21,017 | | | | | 7,883,677 | | | | | | 2020 | | | | | 822,093 | | | | | — | | | | | 3,485,757 | | | | | 4,584,223 | | | | | 554,750 | | | | | 22,610 | | | | | 9,469,433 | | | |||||||||||||||||
Brian Cahill (4) Chief Financial Officer | | | | | 2021 | | | | | 380,000 | | | | | — | | | | | 1,071,649 | | | | | — | | | | | 373,920 | | | | | 30,042 | | | | | 1,855,611 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2020 | | | | | 334,880 | | | | | — | | | | | 658,980 | | | | | 655,111 | | | | | 136,050 | | | | | 29,307 | | | | | 1,814,328 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Michael Moran (5) Chief Commercial Officer | | | | 2021 | | �� | | | | 424,296 | | | | | — | | | | | 987,362 | | | | | — | | | | | 418,540 | | | | | 27,735 | | | | | 1,857,933 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
David Pernock (6) Former President and Chief Operating Officer | | | | | 2021 | | | | | 601,980 | | | | | — | | | | | 1,167,977 | | | | | — | | | | | — | | | | | 1,227,244 | | | | | 2,997,201 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2020 | | | | | 606,530 | | | | | — | | | | | 1,285,485 | | | | | 1,604,636 | | | | | 245,600 | | | | | 44,189 | | | | | 3,786,440 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2019 | | | | | 567,582 | | | | | — | | | | | 886,160 | | | | | 1,003,778 | | | | | 681,100 | | | | | 33,805 | | | | | 3,172,425 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Judith Ng-Cashin, M.D. (7) Former Executive Vice President and Chief Medical Officer | | | | | 2021 | | | | | 465,902 | | | | | — | | | | | 240,820 | | | | | — | | | | | — | | | | | 243,654 | | | | | 950,376 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2020 | | | | | 70,862 | | | | | — | | | | | — | | | | | 832,783 | | | | | 43,050 | | | | | 4,336 | | | | | 951,031 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brian Cahill (5) Chief Financial Officer | | | | | 2022 | | | | | 394,908 | | | | | — | | | | | 1,787,283 | | | | | — | | | | | 177,840 | | | | | 33,316(6) | | | | | 2,493,347 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2021 | | | | | 380,000 | | | | | — | | | | | 1,071,649 | | | | | — | | | | | 373,920 | | | | | 30,042 | | | | | 1,855,611 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2020 | | | | | 334,880 | | | | | — | | | | | 658,980 | | | | | 655,111 | | | | | 136,050 | | | | | 29,307 | | | | | 1,814,328 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Michael Moran (7) Former Chief Commercial Officer | | | | | 2022 | | | | | 277,692 | | | | | — | | | | | 2,310,029 | | | | | — | | | | | — | | | | | 20,604(8) | | | | | 2,608,325 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2021 | | | | | 424,296 | | | | | — | | | | | 987,362 | | | | | — | | | | | 418,540 | | | | | 27,735 | | | | | 1,857,933 | | |
Name | | Type Award(1) | | Grant Date | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards(2) | | Estimated Future Payouts Under Equity Incentive Plan Awards | | | All Other Stock Awards: Number of Shares of Stock or Units (#) | | All Other Option Awards: Number of Securities Underlying Options (#) | | Exercise Price of Option Awards ($/Share) | | Grant Date Fair Value of Stock and Option Awards ($)(4) | | | Type Award(1) | | Grant Date | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards | | Estimated Future Payouts Under Equity Incentive Plan Awards | | | All Other Stock Awards: Number of Shares of Stock or Units (#) | | Grant Date FairValue of Stock and Option Awards($)(2) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Target ($) | | Maximum ($) | | Threshold (#)(3) | | Target (#)(3) | | Maximum(#) | | | Target ($) | | Maximum ($) | | Threshold (#) | | Target (#) | | Maximum (#) | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Scott Tarriff | | | PSU(6) | | | | 02/02/2021 | | | | | — | | | | | — | | | | | | | | | | 25,900 | | | | | 51,800 | | | | | — | | | | | — | | | | | — | | | | $ | 0 | | | | | | | PSU(3) | | | | | 02/28/2022 | | | | | — | | | | | — | | | | | 52,250 | | | | | 104,500 | | | | | 209,000 | | | | | — | | | | | 7,362,025 | | | |||||||||||||||||||||
| PSU(7) | | | | 02/02/2021 | | | | | — | | | | | — | | | | | 30,200 | | | | | 60,400 | | | | | 120,800 | | | | | — | | | | | — | | | | | — | | | | $ | 4,293,836 | | | | | | RSU(4) | | | | | 02/28/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 34,800 | | | | | 1,649,172 | | | ||||||||||||||||||||||||
| PB(8) | | | | 816,280 | | | | | 1,632,560 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | | | | | PB(5) | | | | | | | | | | 848,640 | | | | | 1,697,280 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | | ||||||||||||||||||||||||
Brian Cahill | | | | | RSU(5) | | | | | 02/02/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 8,900 | | | | | — | | | | | — | | | | $ | 438,948 | | | | | | | PSU(3) | | | | | 02/28/2022 | | | | | — | | | | | — | | | | | 12,050 | | | | | 24,100 | | | | | 36,150 | | | | | — | | | | | 1,408,163 | | | ||||||||||||||||||
| PSU(6) | | | | 02/02/2021 | | | | | — | | | | | — | | | | | — | | | | | 7,600 | | | | | 11,400 | | | | | — | | | | | — | | | | | — | | | | $ | 0 | | | | | | RSU(4) | | | | | 02/28/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 8,000 | | | | | 379,120 | | | ||||||||||||||||||||||||
| PSU(7) | | | | 02/02/2021 | | | | | — | | | | | — | | | | | 4,450 | | | | | 8,900 | | | | | 17,800 | | | | | — | | | | | — | | | | | — | | | | $ | 632,701 | | | | | | PB(5) | | | | | | | | | | 237,120 | | | | | 474,240 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | | ||||||||||||||||||||||||
| PB(8) | | | | 228,000 | | | | | 456,000 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Michael Moran | | | RSU(5) | | | | 01/05/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 24,268 | | | | | — | | | | | — | | | | $ | 1,196,898 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PSU(6) | | | | 02/02/2021 | | | | | — | | | | | — | | | | | — | | | | | 7,100 | | | | | 10,650 | | | | | — | | | | | — | | | | | — | | | | $ | 0 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PSU(7) | | | | 02/02/2021 | | | | | — | | | | | — | | | | | 4,100 | | | | | 8,200 | | | | | 16,400 | | | | | — | | | | | — | | | | | — | | | | $ | 582,938 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PB(8) | | | | 255,206 | | | | | 510,412 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
David Pernock Former President and Chief Operating Officer | | | RSU(5) | | | | 02/02/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 9,700 | | | | | — | | | | | — | | | | $ | 478,404 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PSU(6) | | | | 02/02/2021 | | | | | — | | | | | — | | | | | — | | | | | 8,300 | | | | | 14,525 | | | | | — | | | | | — | | | | | — | | | | $ | 0 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PSU(7) | | | | 02/02/2021 | | | | | — | | | | | — | | | | | 4,850 | | | | | 9,700 | | | | | 19,400 | | | | | — | | | | | — | | | | | — | | | | $ | 689,573 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PB(8) | | | | 361,350 | | | | | 722,700 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Judith Ng-Cashin, M.D. Former EVP and Chief Medical Officer | | | RSU(5) | | | | 02/02/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 2,000 | | | | | — | | | | | — | | | | $ | 98,640 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PSU(6) | | | | 02/02/2021 | | | | | — | | | | | — | | | | | — | | | | | 1,700 | | | | | 2,250 | | | | | — | | | | | — | | | | | — | | | | $ | 0 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PSU(7) | | | | 02/02/2021 | | | | | — | | | | | — | | | | | 1,000 | | | | | 2,000 | | | | | 4,000 | | | | | — | | | | | — | | | | | — | | | | $ | 142,180 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PB(8) | | | | 247,230 | | | | | 494,460 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Michael Moran(6) | | | | | PSU(3) | | | | | 02/28/2022 | | | | | — | | | | | — | | | | | 15,550 | | | | | 31,100 | | | | | 46,650 | | | | | — | | | | | 1,817,173 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | RSU(4) | | | | | 02/28/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 10,400 | | | | | 492,856 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | PB(5) | | | | | | | | | | 284,419 | | | | | 568,838 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | |
| | | | | | | Option Awards(1) | | Stock Awards | | | | | | | | Option Awards (1) | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Executive Officer | | Grant Date | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Option Exercise Price Per Share ($)(2)(3) | | Option Expiration Date | | Number of Shares or Units of Stock that Have Not Vested (#)(4) | | Market Value of Shares or Units of Stock that Have Not Vested ($) | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that Have Not Vested (#) | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that Have Not Vested ($) | | | Grant Date | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Option Exercise Price Per Share ($)(2)(3) | | Option Expiration Date | | Number of Shares or Units of Stock that Have Not Vested (#) (4) | | Market Value of Shares or Units of Stock that Have Not Vested ($)(5) | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that Have Not Vested (#) | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that Have Not Vested ($)(5) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Scott Tarriff | | | | | 8/26/2014 | | | | | 75,000 | | | | | — | | | | | 12.63 | | | | | 8/25/2024 | | | | | | | | | | | | | | | | | | | | | | | | | | | 8/26/2014 | | | | | 75,000 | | | | | — | | | | | 12.63 | | | | | 8/25/2024 | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||
| | | 3/13/2015 | | | | | 125,000 | | | | | — | | | | | 46.09 | | | | | 3/12/2025 | | | | | | | | | | | | | | | | | | | | | | | | | | 3/13/2015 | | | | | 125,000 | | | | | — | | | | | 46.09 | | | | | 3/12/2025 | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||
| | | 1/4/2016 | | | | | 180,000 | | | | | — | | | | | 86.15 | | | | | 1/3/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | 1/4/2016 | | | | | 180,000 | | | | | — | | | | | 86.15 | | | | | 1/3/2026 | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||
| | | 1/4/2017 | | | | | 200,900 | | | | | — | | | | | 84.92 | | | | | 1/3/2027 | | | | | | | | | | | | | | | | | | | | | | | | | | 1/4/2017 | | | | | 200,900 | | | | | — | | | | | 84.92 | | | | | 1/3/2027 | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||
| | | 1/7/2018 | | | | | 153,729 | | | | | 3,271 | | | | | 59.14 | | | | | 1/6/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | 1/7/2018 | | | | | 157,000 | | | | | — | | | | | 59.14 | | | | | 1/6/2028 | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||
| | | 1/23/2019 | | | | | 100,042 | | | | | 37,158 | | | | | 42.40 | | | | | 1/22/2029 | | | | | 30,650 | | | | | 1,560,698 | | | | | | | | | | | | | | | | 1/23/2019 | | | | | 134,342 | | | | | 2,858 | | | | | 42.40 | | | | | 1/22/2029 | | | | | 15,325 | | | | | 447,950 | | | | | — | | | | | — | | | |||||||||||||||||||
| | | 1/5/2020 | | | | | 69,815 | | | | | 75,885 | | | | | 59.79 | | | | | 1/4/2030 | | | | | 43,725 | | | | | 2,226,477 | | | | | | | | | | | | | | | | 1/5/2020 | | | | | 106,240 | | | | | 39,460 | | | | | 59.79 | | | | | 1/4/2030 | | | | | 29,150 | | | | | 852,055 | | | | | — | | | | | — | | | |||||||||||||||||||
| | | 2/2/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 25,900(7) | | | | | 1,318,828 | | | | | | 2/2/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 25,900(6) | | | | | 1,318,828 | | | |||||||||||||||||||
| | | 2/2/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 60,400(8) | | | | | 3,075,568 | | | | | | 2/2/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 60,400(7) | | | | | 3,075,568 | | | |||||||||||||||||||
Scott Tarriff | | | | 2/28/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 104,500(8) | | | | | 3,054,535 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/28/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 34,800 | | | | | 1,017,204 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 10/11/2016 | | | | | 10,000 | | | | | — | | | | | 64.70 | | | | | 10/10/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | 10/11/2016 | | | | | 10,000 | | | | | — | | | | | 64.70 | | | | | 10/10/2026 | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||
| | | 1/7/2018 | | | | | 12,240 | | | | | 260 | | | | | 59.14 | | | | | 1/6/2028 | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 1/29/2019 | | | | | 9,943 | | | | | 3,693 | | | | | 41.37 | | | | | 1/28/2029 | | | | | 3,409 | | | | | 173,586 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 1/5/2020 | | | | | 6,229 | | | | | 6,771 | | | | | 59.79 | | | | | 1/4/2030 | | | | | 5,250 | | | | | 267,330 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 12/18/2020 | | | | | 2,500 | | | | | 7,500 | | | | | 48.09 | | | | | 12/17/2030 | | | | | 3,750 | | | | | 190,950 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/2/2021 | | | | | | | | | | | | | | | | | | | | | | | | | 8,900 | | | | | 453,188 | | | | | 7,600(7) | | | | | 386,992 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/2/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,900(8) | | | | | 453,188 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 1/27/2016 | | | | | 10,000 | | | | | — | | | | | 66.32 | | | | | 1/27/2026 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 1/4/2017 | | | | | 27,000 | | | | | — | | | | | 84.92 | | | | | 1/3/2027 | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Michael Moran | | | | 1/7/2018 | | | | | 4,896 | | | | | 104 | | | | | 59.14 | | | | | 1/6/2028 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 1/29/2019 | | | | | 3,281 | | | | | 1,219 | | | | | 41.37 | | | | | 1/29/2029 | | | | | 1,125 | | | | | 57,285 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 1/5/2020 | | | | | 17,969 | | | | | 19,531 | | | | | 59.79 | | | | | 1/5/2030 | | | | | 11,250 | | | | | 572,850 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/2/2021 | | | | | | | | | | | | | | | | | | | | | | | | | 8,200 | | | | | 417,544 | | | | | 7,100(7) | | | | | 361,532 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/2/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,200(8) | | | | | 417,544 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 4/8/2015(5) | | | | | 10,000 | | | | | — | | | | | 46.81 | | | | | 12/31/2022 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 4/21/2015(6) | | | | | 10,000 | | | | | — | | | | | 59.31 | | | | | 12/31/2022 | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
David Pernock | | | | 1/4/2016(6) | | | | | 15,000 | | | | | — | | | | | 86.15 | | | | | 12/31/2022 | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 1/4/2017 | | | | | 90,000 | | | | | — | | | | | 84.92 | | | | | 12/31/2022 | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 1/7/2018 | | | | | 50,000 | | | | | — | | | | | 59.14 | | | | | 12/31/2022 | | | | | 2,500 | | | | | 127,300 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 1/23/2019 | | | | | 45,629 | | | | | — | | | | | 42.40 | | | | | 12/31/2022 | | | | | 5,225 | | | | | 266,057 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 1/5/2020 | | | | | 37,188 | | | | | — | | | | | 59.79 | | | | | 12/31/2022 | | | | | 5,375 | | | | | 273,695 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2/2/2021 | | | | | | | | | | | | | | | | | | | | | | | | | 2,425 | | | | | 123,481 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 10/30/2020 | | | | | 9,479 | | | | | — | | | | | 46.52 | | | | | 6/16/2022 | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 1/7/2018 | | | | | 12,500 | | | | | — | | | | | 59.14 | | | | | 1/6/2028 | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 1/29/2019 | | | | | 13,352 | | | | | 284 | | | | | 41.37 | | | | | 1/28/2029 | | | | | 1,704 | | | | | 49,808 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 1/5/2020 | | | | | 9,479 | | | | | 3,521 | | | | | 59.79 | | | | | 1/4/2030 | | | | | 3,500 | | | | | 102,305 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 12/18/2020 | | | | | 5,417 | | | | | 4,583 | | | | | 48.09 | | | | | 12/17/2030 | | | | | 2,500 | | | | | 73,075 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/2/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 6,675 | | | | | 195,110 | | | | | 7,600(6) | | | | | 386,992 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/2/2021 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 8,900(7) | | | | | 453,188 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/28/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 24,100(8) | | | | | 704,443 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2/28/2022 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 8,000 | | | | | 233,840 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Michael Moran(9) | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | |
| | | Option Awards | | | | | | | | | Stock Awards | | | | | | | | ||||||
Name | | | Number of Shares Acquired on Exercise | | | Value Realized on Exercise ($)(4) | | | Number of Shares Acquired on Vesting | | | Value Realized on Vesting($)(5) | | ||||||||||||
Scott Tarriff | | | | | 31,201 | | | | | | 1,262,080.45 | | | | | | 29,900(1) | | | | | | 1,460,044.00 | | |
Brian Cahill | | | | | — | | | | | | — | | | | | | 5,337(2) | | | | | | 267,249.69 | | |
Michael Moran | | | | | 2,906 | | | | | | 28,653.16 | | | | | | 4,565 | | | | | | 226,698.95 | | |
David Pernock (former President and Chief Operating Officer) | | | | | — | | | | | | — | | | | | | 13,100(3) | | | | | | 645,515.00 | | |
Judith Ng-Cashin, M.D. (former Chief Medical Officer) | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | Option Awards | | | | | | | | | Stock Awards | | | | | | | | ||||||
Name | | | Number of Shares Acquired on Exercise | | | Value Realized on Exercise ($) | | | Number of Shares Acquired on Vesting | | | Value Realized on Vesting ($)(4) | | ||||||||||||
Scott Tarriff | | | | | — | | | | | | — | | | | | | 29,900(1) | | | | | | 1,467,511.00 | | |
Brian Cahill | | | | | — | | | | | | — | | | | | | 7,563(2) | | | | | | 336,813.00 | | |
Michael Moran (Former Chief Commercial Officer) | | | | | — | | | | | | — | | | | | | 6,615(3) | | | | | | 321,027.00 | | |
Name | | Cash Payment ($)(1) | | Accelerated Vesting of Stock Options ($)(2) | | Accelerated Vesting of Restricted Stock Units ($)(3) | | Accelerated Vesting of Performance Share Units ($)(4) | | Health and Other Benefits ($)(5) | | Total ($) | | | Cash Payment ($)(1) | | Accelerated Vesting of Stock Options ($)(2) | | Accelerated Vesting of Restricted Stock Units ($)(3) | | Accelerated Vesting of Performance Share Units ($)(4) | | Health and Other Benefits ($)(5) | | Total ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||
Scott Tarriff | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||
Termination without cause or resignation for good reason other than in the context of a change in control | | | $ | 2,040,700 | | | | $ | 316,586 | | | | $ | 3,787,175 | | | | $ | 6,464,490 | | | | $ | 33,167 | | | | $ | 12,642,118 | | | | | | 2,122,350 | | | | | — | | | | | 2,317,208 | | | | | 5,508,443 | | | | | 34,163 | | | | | 9,982,164 | | | ||||||||||||
Change in control only(6) | | | $ | — | | | | $ | 316,586 | | | | $ | 3,787,175 | | | | $ | 6,464,490 | | | | $ | — | | | | $ | 10,568,251 | | | | | | — | | | | | — | | | | | 2,317,208 | | | | | 5,508,443 | | | | | — | | | | | 7,825,651 | | | ||||||||||||
Change in control with termination without cause or resignation for good reason | | | $ | 3,265,120 | | | | $ | 316,586 | | | | $ | 3,787,175 | | | | $ | 6,464,490 | | | | $ | 44,222 | | | | $ | 13,877,593 | | | | | | 3,395,760 | | | | | — | | | | | 2,317,208 | | | | | 5,508,443 | | | | | 45,550 | | | | | 11,266,961 | | | ||||||||||||
Death or disability | | | $ | — | | | | $ | 316,586 | | | | $ | 3,787,175 | | | | $ | 6,464,490 | | | | $ | — | | | | $ | 10,568,251 | | | | | | — | | | | | — | | | | | 2,317,208 | | | | | 5,508,443 | | | | | — | | | | | 7,825,651 | | | ||||||||||||
Brian Cahill | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||
Termination without cause or resignation for good reason other than in the context of a change in control | | | $ | — | | | | $ | — | | | | $ | — | | | | $ | — | | | | $ | — | | | | $ | — | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||
Change in control only(6) | | | $ | — | | | | $ | 56,493 | | | | $ | 1,117,287 | | | | $ | 1,145,210 | | | | $ | — | | | | $ | 2,318,990 | | | | | | — | | | | | — | | | | | 654,138 | | | | | 1,170,908 | | | | | — | | | | | 1,825,046 | | | ||||||||||||
Change in control with termination without cause or resignation for good reason | | | $ | — | | | | $ | 56,493 | | | | $ | 1,117,287 | | | | $ | 1,145,210 | | | | $ | — | | | | $ | 2,318,990 | | | | | | — | | | | | — | | | | | 654,138 | | | | | 1,170,908 | | | | | — | | | | | 1,825,046 | | | ||||||||||||
Death or disability | | | $ | — | | | | $ | — | | | | $ | — | | | | $ | — | | | | $ | — | | | | $ | — | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||
Michael Moran | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||
Termination without cause or resignation for good reason other than in the context of a change in control | | | $ | 729,280 | | | | $ | 10,744 | | | | $ | 336,836 | | | | $ | 1,060,115 | | | | $ | 3,600 | | | | $ | 2,140,575 | | | |||||||||||||||||||||||||||||||||||||||||||
Change in control only(6) | | | $ | — | | | | $ | 11,641 | | | | $ | 1,060,562 | | | | $ | 1,060,115 | | | | $ | — | | | | $ | 2,132,318 | | | |||||||||||||||||||||||||||||||||||||||||||
Change in control with termination without cause or resignation for good reason | | | $ | 1,093,920 | | | | $ | 11,641 | | | | $ | 1,060,562 | | | | $ | 1,060,115 | | | | $ | 5,400 | | | | $ | 3,231,638 | | | |||||||||||||||||||||||||||||||||||||||||||
Death or disability | | | $ | — | | | | $ | 11,641 | | | | $ | 1,060,562 | | | | $ | 1,060,115 | | | | $ | — | | | | $ | 2,132,318 | | | |||||||||||||||||||||||||||||||||||||||||||
David Pernock(7) | | | $ | 1,216,645 | | | | $ | 107,465 | | | | $ | 790,533 | | | | $ | — | | | | $ | — | | | | $ | 2,114,643 | | | |||||||||||||||||||||||||||||||||||||||||||
Judith Ng-Cashin, M.D.(7) | | | $ | 206,025 | | | | $ | — | | | | $ | — | | | | $ | — | | | | $ | 11,056 | | | | $ | 217,081 | | |
Name(1) | | | Year | | | Fees Earned or Paid in Cash ($) | | | Option Awards ($)(2)(3) | | | Total ($) | | ||||||||||||
Michael Graves | | | | | 2021 | | | | | | 160,000 | | | | | | 330,761 | | | | | | 490,761 | | |
Steven Ratoff | | | | | 2021 | | | | | | 100,000 | | | | | | 330,761 | | | | | | 430,761 | | |
Robert Glenning | | | | | 2021 | | | | | | 86,250 | | | | | | 330,761 | | | | | | 417,011 | | |
Richard A. Edlin | | | | | 2021 | | | | | | 81,250 | | | | | | 330,761 | | | | | | 412,011 | | |
Jennifer Simpson | | | | | 2021 | | | | | | 74,375 | | | | | | 330,761 | | | | | | 405,136 | | |
Luciana Borio(4) | | | | | 2021 | | | | | | 50,125 | | | | | | 285,494 | | | | | | 335,619 | | |
Name(1) | | | Year | | | Fees Earned or Paid in Cash ($) | | | Option Awards ($)(2) | | | Total ($) | | ||||||||||||
Michael Graves | | | | | 2022 | | | | | | 160,000 | | | | | | 231,026 | | | | | $ | 391,026 | | |
Steven Ratoff | | | | | 2022 | | | | | | 100,000 | | | | | | 231,026 | | | | | $ | 331,026 | | |
Robert Glenning | | | | | 2022 | | | | | | 93,750 | | | | | | 231,026 | | | | | $ | 324,776 | | |
Richard A. Edlin | | | | | 2022 | | | | | | 81,250 | | | | | | 231,026 | | | | | $ | 312,276 | | |
Jennifer Simpson | | | | | 2022 | | | | | | 77,500 | | | | | | 231,026 | | | | | $ | 308,526 | | |
Luciana Borio | | | | | 2022 | | | | | | 77,500 | | | | | | 231,026 | | | | | $ | 308,526 | | |
| | | Stock awards (#) | | | Option awards (#) | | ||||||
Michael Graves | | | | | — | | | | | | 123,740 | | |
Steven Ratoff | | | | | — | | | | | | 99,380 | | |
Robert Glenning | | | | | — | | | | | | 74,700 | | |
Richard A. Edlin | | | | | — | | | | | | 64,700 | | |
Jennifer Simpson | | | | | — | | | | | | 44,700 | | |
Luciana Borio | | | | | — | | | | | | 24,700 | | |
Plan Category | | | Number of securities to be issued upon exercise of outstanding options, RSUs and PSUs (a) | | | Weighted-average exercise price of outstanding options (b)(1) | | | Number of securities remaining available for issuance under equity compensation plans (excluding securities reflected in column (a))(c) | | |||||||||
Equity compensation plans approved by security holders | | | | | | | | | | | | | | | | | | | |
2007 Incentive Compensation Plan | | | | | 391,108 | | | | | | 29.09 | | | | | | —(2) | | |
2014 Equity Incentive Plan | | | | | 2,824,376 | | | | | | 54.28 | | | | | | 2,157,175(3) | | |
2014 Employee Stock Purchase Plan | | | | | — | | | | | | — | | | | | | 1,345,283(4) | | |
Equity compensation plans not approved by security holders | | | | | — | | | | | | — | | | | | | — | | |
Total | | | | | 3,215,484 | | | | | | 51.21 | | | | | | 3,502,457 | | |
Plan Category | | | Number of securities to be issued upon exercise of outstanding options, RSUs and PSUs (a) | | | Weighted-average exercise price of outstanding options (b)(1) | | | Number of securities remaining available for issuance under equity compensation plans (excluding securities reflected in column (a))(c) | | |||||||||
Equity compensation plans approved by security holders | | | | | | | | | | | | | | | | | | | |
2007 Incentive Compensation Plan | | | | | 334,861 | | | | | | 31.47 | | | | | | —(2) | | |
2014 Equity Incentive Plan | | | | | 2,679,235 | | | | | | 61.69 | | | | | | 3,176,245(3) | | |
2014 Employee Stock Purchase Plan | | | | | — | | | | | | — | | | | | | 1,475,442(4) | | |
Equity compensation plans not approved by security holders | | | | | — | | | | | | — | | | | | | — | | |
Total | | | | | 3,014,096 | | | | | | 57.51 | | | | | | 4,651,686 | | |
PAY VERSUS PERFORMANCE | | |||||||||||||||||||||||||||||||||||||||||||||
Year | | | Summary Compensation Table Total for PEO(1) ($) | | | Compensation Actually Paid to PEO(2) ($) | | | Average Summary Compensation Table Total for Non-PEO NEOs(3) ($) | | | Average Compensation Actually Paid to Non-PEO NEOs(4) ($) | | | Value of Initial Fixed $100 Investment Based On: | | | Net Income (thousands)(7) ($) | | | 1-Year Relative TSR(8) (percentile rank) | | ||||||||||||||||||||||||
| Total Shareholder Return(5) ($) | | | Peer Group Total Shareholder Return(6) ($) | | |||||||||||||||||||||||||||||||||||||||||
2022 | | | | | 10,520,577 | | | | | | 1,199,578 | | | | | | 2,550,836 | | | | | | (244,944) | | | | | | 48.65 | | | | | | 113.65 | | | | | | 35,642 | | | | 55.0th percentile | |
2021 | | | | | 6,471,521 | | | | | | 6,927,682 | | | | | | 1,915,280 | | | | | | 1,256,974 | | | | | | 84.75 | | | | | | 126.45 | | | | | | (8,627) | | | | 79.7th percentile | |
2020 | | | | | 9,469,433 | | | | | | 997,889 | | | | | | 2,774,794 | | | | | | 86,282 | | | | | | 77.51 | | | | | | 126.42 | | | | | | 11,989 | | | | 22.9th percentile | |
Year | | | Reported Summary Compensation Table Total for PEO ($) | | | Deduct: Reported Value of Equity Awards(a) ($) | | | Add: Equity Award Adjustments(b) ($) | | | Compensation Actually Paid to PEO ($) | | ||||||||||||
2022 | | | | | 10,520,577 | | | | | | 9,011,197 | | | | | | (309,802) | | | | | | 1,199,578 | | |
2021 | | | | | 6,471,521 | | | | | | 4,293,836 | | | | | | 4,749,997 | | | | | | 6,927,682 | | |
2020 | | | | | 9,469,433 | | | | | | 8,069,980 | | | | | | (401,564) | | | | | | 997,889 | | |
Year | | | Add: Year End Fair Value of Outstanding and Unvested Equity Awards Granted in the Year ($) | | | Add: Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years ($) | | | Add: Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year ($) | | | Add: Change in Fair Value as of the Vesting Date of Equity Awards Granted in Prior Years that Vested in the Year ($) | | | Deduct: Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Applicable Vesting Conditions in the Year ($) | | | Total Equity Award Adjustments ($)(a) | | ||||||||||||||||||
2022 | | | | | 4,350,754 | | | | | | (4,128,048) | | | | | | — | | | | | | (532,507) | | | | | | — | | | | | | (309,802) | | |
2021 | | | | | 4,783,076 | | | | | | 8,397 | | | | | | — | | | | | | (41,476) | | | | | | — | | | | | | 4,749,997 | | |
2020 | | | | | 5,343,957 | | | | | | (4,161,264) | | | | | | — | | | | | | (1,584,257) | | | | | | — | | | | | | (401,564) | | |
Year | | | Average Reported Summary Compensation Table Total for Non-PEO NEOs ($) | | | Deduct: Average Reported Value of Equity Awards(a) ($) | | | Add: Average Equity Award Adjustments ($) | | | Average Compensation Actually Paid to Non-PEO NEOs ($) | | ||||||||||||
2022 | | | | | 2,550,836 | | | | | | 2,048,656 | | | | | | (747,124) | | | | | | (244,944) | | |
2021 | | | | | 1,915,280 | | | | | | 866,952 | | | | | | 208,646 | | | | | | 1,256,974 | | |
2020 | | | | | 2,774,794 | | | | | | 2,175,719 | | | | | | (512,793) | | | | | | 86,282 | | |
Year | | | Add: Average Year End Fair Value of Outstanding and Unvested Equity Awards Granted in the Year ($) | | | Add: Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years ($) | | | Add: Average Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year ($) | | | Add: Average Change in Fair Value as of the Vesting Date of Equity Awards Granted in Prior Years that Vested in the Year ($) | | | Deduct: Average Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Applicable Vesting Conditions in the Year ($) | | | Total Average Equity Award Adjustments ($)(a) | | ||||||||||||||||||
2022 | | | | | 462,394 | | | | | | (412,424) | | | | | | — | | | | | | (71,322) | | | | | | 725,771 | | | | | | (747,124) | | |
2021 | | | | | 556,220 | | | | | | 3,241 | | | | | | 30,870 | | | | | | (4,618) | | | | | | 377,068 | | | | | | 208,646 | | |
2020 | | | | | 637,954 | | | | | | (269,573) | | | | | | 49,463 | | | | | | (248,968) | | | | | | 681,669 | | | | | | (512,793) | | |
| | | Twelve Months Ended December 31, | | |||||||||
| | | 2021 | | | 2020 | | ||||||
Net (loss) income – GAAP | | | | $ | (8,627) | | | | | $ | 11,989 | | |
Adjustments: | | | | | | | | | | | | | |
Cost of product revenues: | | | | | | | | | | | | | |
Amortization expense | | | | | 1,578 | | | | | | 1,046 | | |
Research and development: | | | | | | | | | | | | | |
Stock-based compensation expense | | | | | 2,682 | | | | | | 2,682 | | |
Depreciation expense | | | | | 220 | | | | | | 269 | | |
Expense of acquired in-process research & development | | | | | 15,339 | | | | | | — | | |
Severance | | | | | 534 | | | | | | — | | |
Selling, general and administrative: | | | | | | | | | | | | | |
Stock-based compensation expense | | | | | 16,873 | | | | | | 22,074 | | |
Expense related to collaboration with Tyme | | | | | — | | | | | | 2,500 | | |
Amortization expense | | | | | 1,418 | | | | | | 1,620 | | |
Depreciation expense | | | | | 544 | | | | | | 603 | | |
Severance | | | | | 1,550 | | | | | | 924 | | |
Other: | | | | | | | | | | | | | |
Non-cash interest expense | | | | | 472 | | | | | | 472 | | |
Fair value adjustments on equity investment | | | | | 6,170 | | | | | | 5,300 | | |
Convertible promissory note related credit losses | | | | | 758 | | | | | | — | | |
Fair value adjustments related to derivative instrument | | | | | (686) | | | | | | 2,962 | | |
Accretion of discount on convertible promissory note | | | | | (148) | | | | | | — | | |
Tax effect of the non-GAAP adjustments | | | | | (4,276) | | | | | | (3,699) | | |
Adjusted non-GAAP net income | | | | $ | 34,401 | | | | | $ | 48,742 | | |
Adjusted non-GAAP earnings per share: | | | | | | | | | | | | | |
Basic | | | | $ | 2.64 | | | | | $ | 3.62 | | |
Diluted | | | | $ | 2.59 | | | | | $ | 3.54 | | |
Weighted average number of common shares outstanding: | | | | | | | | | | | | | |
Basic | | | | | 13,051,095 | | | | | | 13,481,525 | | |
Diluted | | | | | 13,265,181 | | | | | | 13,771,393 | | |
| | | Twelve Months Ended December 31, | | |||||||||
| | | 2021 | | | 2020 | | ||||||
Net (loss) income – GAAP | | | | $ | (8,627) | | | | | $ | 11,989 | | |
Add back: | | | | | | | | | | | | | |
Interest expense, net of interest income | | | | | 1,075 | | | | | | 2,015 | | |
Income tax provision | | | | | 4,079 | | | | | | 10,688 | | |
Depreciation and amortization expense | | | | | 3,760 | | | | | | 3,538 | | |
Add back: | | | | | | | | | | | | | |
Stock-based compensation expense | | | | | 19,555 | | | | | | 24,756 | | |
Fair value adjustments on equity investment | | | | | 6,170 | | | | | | 5,300 | | |
Expense of acquired in-process research & development | | | | | 15,339 | | | | | | — | | |
Convertible promissory note related credit losses | | | | | 758 | | | | | | — | | |
Fair value adjustments related to derivative instrument | | | | | (686) | | | | | | 2,962 | | |
Expense related to collaboration with Tyme | | | | | — | | | | | | 2,500 | | |
Severance | | | | | 2,084 | | | | | | 924 | | |
Adjusted Non-GAAP EBITDA | | | | $ | 43,507 | | | | | $ | 64,672 | | |